Cargando…
Preclinical Testing of a Vaccine Candidate against Tularemia
Tularemia is caused by a gram-negative, intracellular bacterial pathogen, Francisella tularensis (Ft). The history weaponization of Ft in the past has elevated concerns that it could be used as a bioweapon or an agent of bioterrorism. Since the discovery of Ft, three broad approaches adopted for tul...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405390/ https://www.ncbi.nlm.nih.gov/pubmed/25897786 http://dx.doi.org/10.1371/journal.pone.0124326 |
_version_ | 1782367634827771904 |
---|---|
author | Suresh, Ragavan Varadharajan Ma, Zhuo Sunagar, Raju Bhatty, Vivek Banik, Sukalyani Catlett, Sally V. Gosselin, Edmund J. Malik, Meenakshi Bakshi, Chandra Shekhar |
author_facet | Suresh, Ragavan Varadharajan Ma, Zhuo Sunagar, Raju Bhatty, Vivek Banik, Sukalyani Catlett, Sally V. Gosselin, Edmund J. Malik, Meenakshi Bakshi, Chandra Shekhar |
author_sort | Suresh, Ragavan Varadharajan |
collection | PubMed |
description | Tularemia is caused by a gram-negative, intracellular bacterial pathogen, Francisella tularensis (Ft). The history weaponization of Ft in the past has elevated concerns that it could be used as a bioweapon or an agent of bioterrorism. Since the discovery of Ft, three broad approaches adopted for tularemia vaccine development have included inactivated, live attenuated, or subunit vaccines. Shortcomings in each of these approaches have hampered the development of a suitable vaccine for prevention of tularemia. Recently, we reported an oxidant sensitive mutant of Ft LVS in putative EmrA1 (FTL_0687) secretion protein. The emrA1 mutant is highly sensitive to oxidants, attenuated for intramacrophage growth and virulence in mice. We reported that EmrA1 contributes to oxidant resistance by affecting the secretion of antioxidant enzymes SodB and KatG. This study investigated the vaccine potential of the emrA1 mutant in prevention of respiratory tularemia caused by Ft LVS and the virulent SchuS4 strain in C57BL/6 mice. We report that emrA1 mutant is safe and can be used at an intranasal (i. n.) immunization dose as high as 1x10(6) CFU without causing any adverse effects in immunized mice. The emrA1 mutant is cleared by vaccinated mice by day 14–21 post-immunization, induces minimal histopathological lesions in lungs, liver and spleen and a strong humoral immune response. The emrA1 mutant vaccinated mice are protected against 1000–10,000LD(100) doses of i.n. Ft LVS challenge. Such a high degree of protection has not been reported earlier against respiratory challenge with Ft LVS using a single immunization dose with an attenuated mutant generated on Ft LVS background. The emrA1 mutant also provides partial protection against i.n. challenge with virulent Ft SchuS4 strain in vaccinated C57BL/6 mice. Collectively, our results further support the notion that antioxidants of Ft may serve as potential targets for development of effective vaccines for prevention of tularemia. |
format | Online Article Text |
id | pubmed-4405390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44053902015-05-07 Preclinical Testing of a Vaccine Candidate against Tularemia Suresh, Ragavan Varadharajan Ma, Zhuo Sunagar, Raju Bhatty, Vivek Banik, Sukalyani Catlett, Sally V. Gosselin, Edmund J. Malik, Meenakshi Bakshi, Chandra Shekhar PLoS One Research Article Tularemia is caused by a gram-negative, intracellular bacterial pathogen, Francisella tularensis (Ft). The history weaponization of Ft in the past has elevated concerns that it could be used as a bioweapon or an agent of bioterrorism. Since the discovery of Ft, three broad approaches adopted for tularemia vaccine development have included inactivated, live attenuated, or subunit vaccines. Shortcomings in each of these approaches have hampered the development of a suitable vaccine for prevention of tularemia. Recently, we reported an oxidant sensitive mutant of Ft LVS in putative EmrA1 (FTL_0687) secretion protein. The emrA1 mutant is highly sensitive to oxidants, attenuated for intramacrophage growth and virulence in mice. We reported that EmrA1 contributes to oxidant resistance by affecting the secretion of antioxidant enzymes SodB and KatG. This study investigated the vaccine potential of the emrA1 mutant in prevention of respiratory tularemia caused by Ft LVS and the virulent SchuS4 strain in C57BL/6 mice. We report that emrA1 mutant is safe and can be used at an intranasal (i. n.) immunization dose as high as 1x10(6) CFU without causing any adverse effects in immunized mice. The emrA1 mutant is cleared by vaccinated mice by day 14–21 post-immunization, induces minimal histopathological lesions in lungs, liver and spleen and a strong humoral immune response. The emrA1 mutant vaccinated mice are protected against 1000–10,000LD(100) doses of i.n. Ft LVS challenge. Such a high degree of protection has not been reported earlier against respiratory challenge with Ft LVS using a single immunization dose with an attenuated mutant generated on Ft LVS background. The emrA1 mutant also provides partial protection against i.n. challenge with virulent Ft SchuS4 strain in vaccinated C57BL/6 mice. Collectively, our results further support the notion that antioxidants of Ft may serve as potential targets for development of effective vaccines for prevention of tularemia. Public Library of Science 2015-04-21 /pmc/articles/PMC4405390/ /pubmed/25897786 http://dx.doi.org/10.1371/journal.pone.0124326 Text en © 2015 Suresh et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Suresh, Ragavan Varadharajan Ma, Zhuo Sunagar, Raju Bhatty, Vivek Banik, Sukalyani Catlett, Sally V. Gosselin, Edmund J. Malik, Meenakshi Bakshi, Chandra Shekhar Preclinical Testing of a Vaccine Candidate against Tularemia |
title | Preclinical Testing of a Vaccine Candidate against Tularemia |
title_full | Preclinical Testing of a Vaccine Candidate against Tularemia |
title_fullStr | Preclinical Testing of a Vaccine Candidate against Tularemia |
title_full_unstemmed | Preclinical Testing of a Vaccine Candidate against Tularemia |
title_short | Preclinical Testing of a Vaccine Candidate against Tularemia |
title_sort | preclinical testing of a vaccine candidate against tularemia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405390/ https://www.ncbi.nlm.nih.gov/pubmed/25897786 http://dx.doi.org/10.1371/journal.pone.0124326 |
work_keys_str_mv | AT sureshragavanvaradharajan preclinicaltestingofavaccinecandidateagainsttularemia AT mazhuo preclinicaltestingofavaccinecandidateagainsttularemia AT sunagarraju preclinicaltestingofavaccinecandidateagainsttularemia AT bhattyvivek preclinicaltestingofavaccinecandidateagainsttularemia AT baniksukalyani preclinicaltestingofavaccinecandidateagainsttularemia AT catlettsallyv preclinicaltestingofavaccinecandidateagainsttularemia AT gosselinedmundj preclinicaltestingofavaccinecandidateagainsttularemia AT malikmeenakshi preclinicaltestingofavaccinecandidateagainsttularemia AT bakshichandrashekhar preclinicaltestingofavaccinecandidateagainsttularemia |